Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing

Diana Mandelker, Paola Cin, Heather A. Jacene, Philippe Armand, Richard M. Stone, Neal I. Lindeman

Research output: Contribution to journalArticle

Abstract

Next generation sequencing (NGS) is increasingly being used clinically to characterize the molecular alterations found in patients' tumors. These testing results have the potential to affect clinical care by guiding therapeutic approaches based upon genotype. NGS based testing approaches have a distinct advantage over provider-ordered single gene testing in that they can detect unexpected, yet clinically important genetic changes. Here, we illustrate this principle with the case of a 33-year-old man with myeloid sarcoma that was refractory to six different chemotherapeutic regimens. Our clinical NGS assay detected an unanticipated FIP1L1-PDGFRA rearrangement in his tumor. The patient was immediately placed on Imatinib therapy to which he responded, and remains in remission 10 months after the rearrangement was initially detected.

Original languageEnglish (US)
Article number30
JournalExperimental Hematology and Oncology
Volume4
Issue number1
DOIs
StatePublished - Oct 8 2015
Externally publishedYes

Fingerprint

Myeloid Sarcoma
Neoplasms
Genotype
Therapeutics
Genes
Imatinib Mesylate

Keywords

  • FIP1L1-PDGFRA
  • Myeloid sarcoma
  • Next generation sequencing
  • Somatic sequencing

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. / Mandelker, Diana; Cin, Paola; Jacene, Heather A.; Armand, Philippe; Stone, Richard M.; Lindeman, Neal I.

In: Experimental Hematology and Oncology, Vol. 4, No. 1, 30, 08.10.2015.

Research output: Contribution to journalArticle

Mandelker, Diana ; Cin, Paola ; Jacene, Heather A. ; Armand, Philippe ; Stone, Richard M. ; Lindeman, Neal I. / Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. In: Experimental Hematology and Oncology. 2015 ; Vol. 4, No. 1.
@article{0cbc1e0cd3d240289dd3c951581d7ece,
title = "Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing",
abstract = "Next generation sequencing (NGS) is increasingly being used clinically to characterize the molecular alterations found in patients' tumors. These testing results have the potential to affect clinical care by guiding therapeutic approaches based upon genotype. NGS based testing approaches have a distinct advantage over provider-ordered single gene testing in that they can detect unexpected, yet clinically important genetic changes. Here, we illustrate this principle with the case of a 33-year-old man with myeloid sarcoma that was refractory to six different chemotherapeutic regimens. Our clinical NGS assay detected an unanticipated FIP1L1-PDGFRA rearrangement in his tumor. The patient was immediately placed on Imatinib therapy to which he responded, and remains in remission 10 months after the rearrangement was initially detected.",
keywords = "FIP1L1-PDGFRA, Myeloid sarcoma, Next generation sequencing, Somatic sequencing",
author = "Diana Mandelker and Paola Cin and Jacene, {Heather A.} and Philippe Armand and Stone, {Richard M.} and Lindeman, {Neal I.}",
year = "2015",
month = "10",
day = "8",
doi = "10.1186/s40164-015-0026-x",
language = "English (US)",
volume = "4",
journal = "Experimental Hematology and Oncology",
issn = "2162-3619",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing

AU - Mandelker, Diana

AU - Cin, Paola

AU - Jacene, Heather A.

AU - Armand, Philippe

AU - Stone, Richard M.

AU - Lindeman, Neal I.

PY - 2015/10/8

Y1 - 2015/10/8

N2 - Next generation sequencing (NGS) is increasingly being used clinically to characterize the molecular alterations found in patients' tumors. These testing results have the potential to affect clinical care by guiding therapeutic approaches based upon genotype. NGS based testing approaches have a distinct advantage over provider-ordered single gene testing in that they can detect unexpected, yet clinically important genetic changes. Here, we illustrate this principle with the case of a 33-year-old man with myeloid sarcoma that was refractory to six different chemotherapeutic regimens. Our clinical NGS assay detected an unanticipated FIP1L1-PDGFRA rearrangement in his tumor. The patient was immediately placed on Imatinib therapy to which he responded, and remains in remission 10 months after the rearrangement was initially detected.

AB - Next generation sequencing (NGS) is increasingly being used clinically to characterize the molecular alterations found in patients' tumors. These testing results have the potential to affect clinical care by guiding therapeutic approaches based upon genotype. NGS based testing approaches have a distinct advantage over provider-ordered single gene testing in that they can detect unexpected, yet clinically important genetic changes. Here, we illustrate this principle with the case of a 33-year-old man with myeloid sarcoma that was refractory to six different chemotherapeutic regimens. Our clinical NGS assay detected an unanticipated FIP1L1-PDGFRA rearrangement in his tumor. The patient was immediately placed on Imatinib therapy to which he responded, and remains in remission 10 months after the rearrangement was initially detected.

KW - FIP1L1-PDGFRA

KW - Myeloid sarcoma

KW - Next generation sequencing

KW - Somatic sequencing

UR - http://www.scopus.com/inward/record.url?scp=84978023498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978023498&partnerID=8YFLogxK

U2 - 10.1186/s40164-015-0026-x

DO - 10.1186/s40164-015-0026-x

M3 - Article

C2 - 26457233

AN - SCOPUS:84978023498

VL - 4

JO - Experimental Hematology and Oncology

JF - Experimental Hematology and Oncology

SN - 2162-3619

IS - 1

M1 - 30

ER -